Centers for Disease Control - Vaccine Resources
Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots HHS public health and medical experts released a joint statement on the plan for COVID-19 booster doses. HHS, CDC, and FDA continue to study data to understand how long vaccine protection lasts.
Families: Use v-safe after COVID-19 vaccination (Video) — CDC’s v-safe tool uses text messages and surveys to check in with you after you get a COVID-19 vaccine. You can quickly tell CDC how you’re feeling after each dose – including the newly recommended booster dose. And parents and guardians can enroll their adolescents (ages 12 and older) in v-safe. Learn more about v-safe and how to register in this new video and on CDC’s website.
Morbidity and Mortality Weekly Report (MMWR) — Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021 — Real-world evaluations have demonstrated high effectiveness of vaccines against COVID-19–associated hospitalizations measured shortly after vaccination; longer follow-up is needed to assess durability of protection. In an evaluation at 21 hospitals in 18 states, the duration of mRNA vaccine (Pfizer-BioNTech or Moderna) effectiveness against COVID-19 – associated hospitalizations was assessed among adults aged ?18 years. You can learn more here: Morbidity and Mortality Weekly Report
Morbidity and Mortality Weekly Report (MMWR) — New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021 — In this study, the New York State Department of Health linked statewide immunization, laboratory testing, and hospitalization databases for New York to estimate rates of new laboratory-confirmed COVID-19 cases and hospitalizations by vaccination status among adults, as well as corresponding vaccine effectiveness for full vaccination in the population, across all three authorized vaccine products. You can learn more here: Morbidity and Mortality Weekly Report
Morbidity and Mortality Weekly Report (MMWR) — Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021 — Following rapid distribution and administration of the mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) under an Emergency Use Authorization by the Food and Drug Administration, observational studies among nursing home residents demonstrated vaccine effectiveness (VE) ranging from 53% to 92% against SARS-CoV-2 infection. However, concerns about the potential for waning vaccine-induced immunity and the recent emergence of the highly transmissible SARS-CoV-2 B.1.617.2 (Delta) variant highlight the need to continue to monitor VE. You can learn more here: Morbidity and Mortality Weekly Report
Frequently Asked Questions: COVID-19 vaccine boosters — HHS announced a plan to begin offering COVID-19 vaccine booster shots this fall. CDC’s independent advisory committee, the Advisory Committee on Immunization Practices (ACIP), will continue to meet and discuss data on the evolution of the pandemic and the use of COVID-19 vaccines. ACIP will make further recommendations on the use of boosters for the public after a thorough review of the evidence. Frequently asked questions for COVID-19 vaccine boosters are available on C/SNA Essentials page under Media Talking Points, here.